Quantum Genesis AI Clarifies Research Activities and Intellectual Property Rights

Quantum Genesis AI Corp. issued a clarification distinguishing its research activities from those of Quantumzyme LLP and affirming its ownership of intellectual property transferred via a 2023 asset purchase agreement.

LA Metrowire Staff
Technology
Quantum Genesis AI Clarifies Research Activities and Intellectual Property Rights

Quantum Genesis AI Corp. (OTC: QGAI) issued a statement on May 19, 2026, to clarify certain disclosures related to its research activities and intellectual property. The company, which focuses on enzyme engineering, molecular modeling, and biocatalysis, sought to distinguish its work from that of Quantumzyme LLP, a separate entity based in Bengaluru, India, which is not a subsidiary or affiliate of Quantum Genesis AI.

According to the press release, prior announcements on November 5, 2025, and February 12, 2026, referenced scientific publications in the company's broader field. Those publications identified Quantumzyme LLP and reflected the affiliations of researchers at the time of submission. The company now clarifies that those publications are not directly attributable to Quantum Genesis AI but are related to the broader scientific field.

The clarification stems from an Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment filed on April 29, 2026. Under these agreements, Naveen Kulkarni, the company's CEO, transferred to Quantum Genesis AI certain intellectual property, know-how, methodologies, and related rights associated with its core enzyme engineering and biocatalysis business. The company believes that any research conducted by Mr. Kulkarni—whether directly or through Quantumzyme LLP—that is based on or derived from the transferred technology platform falls within the scope of the rights transferred to the company.

This announcement is important because it addresses potential investor confusion regarding the ownership of key intellectual property. By clearly delineating the relationship between Quantum Genesis AI and Quantumzyme LLP, the company aims to reinforce its control over the technology central to its business strategy. The clarification also highlights the company's commitment to transparency, as it relies on advanced data-driven tools and AI to support research and development.

For more information, the company directs readers to its website at https://qgaicorp.com/ and its profile at https://www.otcmarkets.com/stock/QGAI.

The company also included a disclaimer cautioning that forward-looking statements involve risks and uncertainties, and that past performance is not indicative of future results. The press release was issued via NewMediaWire and is available at https://www.newmediawire.com.